Conclusions: Th17 CD39+ cells in juvenile AILD are both quantitatively decreased and qualitatively deficient. Low levels CD39 and A2A expression may contribute to the perpetuation of Th17 cell effector properties and unfettered inflammation in this disease.
Results: CD39 + Th17 (Th17 CD39+ ) cells from HS appear activated and contain high frequencies of lymphocytes producing regulatory cytokines. In AILD, however, Th17 CD39+ cells are markedly diminished and fail to generate AMP/adenosine, thereby limiting control of both target cell proliferation and IL-17 production. When compared to HS, Th17 cells from AILD patients also show lower A2A adenosine receptor expression while displaying similar levels of PDE4A, PDE4B and ADA. Only rare Th17 CD39+ cells are observed by liver immunohistochemistry.
INTRODUCTION
T helper type 17 (Th17) cells are an effector subset that develops in parallel with Th1 and Th2 cell lineages. Th17 cells differentiate from CD4 cell progenitors upon exposure to IL-6, TGF-β and IL-21 in mice, and IL-6, TGF-β and IL-1β in humans [1, 2] . Th17 cells are thought to develop under the influence of RORγt transcription factor, which induces transcription of the IL-17 gene in naïve T helper cells. RORγt acts in cooperation with other transcription factors, such as ROR-α, the signal transducer and activator of transcription 3 (STAT-3), interferon regulatory factor 4 (IRF-4) and runt-related transcription factor 1 (Runx1) to achieve comprehensive differentiation of naïve T-cell precursors into the Th17 lineage [3] [4] [5] [6] .
Th17 cells are involved in a number of inflammatory and autoimmune conditions in mice and humans, including rheumatoid arthritis [7] , psoriasis [8] , multiple sclerosis [9] and inflammatory bowel disease (IBD) [10] . Involvement of Th17 cells in the perpetration of tissue damage has been also reported in autoimmune liver disease (AILD), including autoimmune hepatitis (AIH), where increased levels of serum IL-17 and higher proportions of liver infiltrating IL-17 producing cells are observed [11] . Autoimmune sclerosing cholangitis (ASC) is a childhood autoimmune liver overlap condition in which features of classical AIH type 1, namely hypergammaglobulinaemia, positivity for antinuclear antibody (ANA) and/or anti-smooth muscle antibody (SMA) and interface hepatitis on histology, all co-exist with bile duct abnormalities noted on cholangiography or pathological examination [12] . In AISC there is a strong positive correlation between frequency of Th17 cells and gamma-glutamyl transferase (γGT) as well as alkaline phosphatase (ALP) levels [13] .
In Th17 cells expression of CD39, an ectonucleotidase that initiates the major extracellular ATP/ADP hydrolysis cascade culminating in the generation of immunosuppressive adenosine [14, 15] , is associated with the acquisition of regulatory properties. This pattern of CD39 expression appears mechanistic in controlling the pathogenic potential of these cells [16] .
Distinct from the prototypic 'effector' Th17 cells, Th17 cells positive for CD39 (Th17 CD39+ ) display regulatory properties such as expression of FOXP3 and suppression of responder cell effector function, while retaining phenotypic (i.e. IL-17 production and RORγt expression) and ectoenzymatic (i.e. generation of inosine from adenosine because of high levels of adenosine deaminase, ADA) features typical of effector cells [16] . The joint expression of regulatory and effector properties suggest that Th17 CD39+ cells can act as either effectors or regulators depending on the milieu in which these cells are located.
We have previously shown that patients with AIH have impaired CD39 + regulatory Tcells (T-regs), which are defective in suppressing IL-17 production by responder cells possibly as a result of low adenosine generation [17] .
In this study, we have aimed to determine the proportion, phenotypic and functional properties of circulating Th17 CD39+ cells in patients with ANA/SMA positive juvenile AILD and to investigate whether low levels of CD39 expression are associated with persistence of Th17 cells at an inflammatory state.
MATERIALS AND METHODS

Subjects
Thirty-eight patients with anti-nuclear (ANA) and/or anti-smooth muscle (SMA) positive AILD were studied. Seventeen patients were female. A liver biopsy performed at the time of or close to diagnosis showed histological features of interface hepatitis in all patients.
All patients underwent cholangiography to assess bile duct integrity and intestinal endoscopic examination to exclude inflammatory bowel disease (IBD) at the time of or close to the diagnosis of AILD [12] . Sixteen of the thirty-eight patients had bile duct changes characteristic of sclerosing cholangitis on retrograde or magnetic resonance cholangiography and were diagnosed as having ASC [12] . Thirteen of the 22 AIH Table 1 . Patients were treated with prednisolone (2.5-5 mg daily at remission and 1-2 mg/kg/day at relapse) either alone or in combination with azathioprine (1-2 mg/kg/day). In two patients prednisolone was used in combination with mycophenolate mofetil (MMF, 40 mg/kg/day). In ASC, ursodeoxycholic acid (UDCA) at a dose of 15-20 mg/kg/day was added to the immunosuppressive regimen. Eight subjects with liver disorders of non-autoimmune and non-viral etiology served as disease controls (DC) (7 females, median age 15 years [range 6-25 years; 2 non-alcoholic fatty liver disease (NAFLD), 1 α-1 antitrypsin deficiency, 1 Gilbert syndrome, 1 Wilson disease, 1 congenital portosystemic shunt, 1 Alagille syndrome, 1 hepatic adenoma]. Sixteen healthy subjects (HS) (10 females, median age 29 years [range 23-46 years]) served as normal controls. Age differences between patients and HS were a consequence of ethical concern in obtaining blood from healthy children. Informed consent was obtained from all patients -or guardians if they were younger than 16 years of age -and from controls.
The study was approved by the Ethics Committee of King's College Hospital, London, United Kingdom.
Cell separation
Peripheral blood mononuclear cells (PBMCs) were obtained as previously described [18] .
Mononuclear cell viability exceeded 98% as determined by Trypan blue exclusion.
Flow cytometry
The frequency and phenotype of Th17 cells was determined by flow cytometry [16] .
PBMCs were stained with allophycocyanin (APC)-cychrome (Cy)-7-conjugated anti- PerCP-conjugated anti-TGF-β (clone # 27232) (R&D Systems, Abingdon, UK) monoclonal antibodies. Flow cytometry was performed, as indicated above.
Cell purification
Th17 cells were purified using the IL-17 secretion assay-detection kit (Miltenyi Biotec, Bergisch-Gladback, Germany) according to the manufacturer's instructions. Th17 cells were then further purified according to the expression of CD39. Briefly, Th17 cells were incubated with PE-conjugated anti-CD39 for 30 minutes, then with microbeads conjugated with monoclonal anti-PE antibodies (Miltenyi Biotec) for 15 minutes at 4ºC.
The Th17 CD39+ and Th17 CD39cell populations were respectively purified by positive and negative selection using MS columns (Miltenyi Biotec) according to the manufacturer's instructions. The purity of Th17 CD39+ and Th17 CD39cells was consistently higher than 92%. CD4 + cells and CD4 + CD25cells to be used in cell polarization experiments (CD4 cells) and suppression assays as target cells (CD4 + CD25cells) were purified from PBMCs using immunomagnetic beads (Dynal Invitrogen, Oslo, Norway) as previously described [18, 19] . The purity of CD4 + and CD4 + CD25cells exceeded 95%.
Suppression assays
Th17 CD39+ and Th17 CD39cells were added at ratios of 1/8 to CD4 + CD25cells [16] .
Parallel cultures of CD4 + CD25cells alone were set up under identical conditions. Cells were co-cultured at 37ºC and 5% CO 2 for 5 days in the presence of anti-CD3/anti-CD28 T-cell expander (Dynal Invitrogen) (ratio bead/cell: 1/2) and IL-2 (30 U/ml). Suppression was assessed as both inhibition of target cell proliferation and decrease in proinflammatory cytokine (e.g. IL-17, IFNγ) levels. In the proliferation assay, experiments were performed in duplicate. For the last 18 hours of culture, cells were pulsed with 0.25 µCi/well 3 H-thymidine and harvested using a multi-channel harvester. Percentage inhibition was calculated using the formula: [1 -count per minute (cpm) in the presence of Th17 CD39+ /Th17 CD39cells]. As previously shown [17] , the 3 H-thymidine incorporation method was chosen as we were dealing with low yield cell samples.
Cell polarization
Expression of A1, A2A, A2B, A3 adenosine receptors, PDE4A, PDE4B and adenosine deaminase (ADA) (see below) were determined on Th17 cells obtained from purified CD4 + cells following exposure to Th17 polarizing conditions. Culture conditions favoring the development of Th17 cells consisted of exposure to anti-CD3/anti-CD28 Tcell expander (ratio bead/cell: 1/50), recombinant human (rh) IL-23 (20 ng/ml), IL-6 (50 ng/ml), IL-1β (10 ng/ml) and TGF-β (3 ng/ml) (all recombinant cytokines were from R&D Systems) for 4 days.
Immunohistochemistry
Paraffin embedded liver sections, obtained from 7 biopsy specimens (6 from [A] patients, 1 from [R] patient) were processed as previously described [13] , then incubated overnight at 4ºC with anti-CD4 (mouse monoclonal, 4B12, Dako, Denmark) and anti-ENTPD1 (rabbit polyclonal, Sigma Aldrich) primary antibodies, used at 1/30 and 1/100 respectively. After endogenous peroxidase blocking with 3% H 2 O 2 , sections were incubated with horse anti-mouse and goat anti-rabbit secondary antibodies (Vector Laboratories, Burlingame, CA), used at 1/250 and 1/800 for 1 hour at room temperature.
After treatment with Vectastain Elite ABC kit (Vector Laboratories), ImmPACT DAB (Vector Laboratories) was applied and sections examined by light microscopy.
For immunofluorescence staining, following blocking and incubation with primary antibodies, sections were probed with AlexaFluor 488 (Jackson ImmunoResearch Laboratories, West Grove, PA) and AlexaFluor 594 labeled secondary antibodies (Molecular Probes, Thermo-Scientific, Rockford, IL), used at 1/500 and 1/300 respectively. Hoechst staining was used to identify nuclei. Staining was then analyzed by Zeiss ApoTome Immunofluorescence microscope.
Quantitative real-time PCR
Expression of A1, A2A, A2B and A3 adenosine receptors and of PDE4A and PDE4B was determined by real-time PCR. Total RNA was extracted from 2-3×10 5 cells using TRIzol reagent (Invitrogen) and mRNA was reverse transcribed using iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA), according to the manufacturer's instructions. Primer sequences of adenosine receptors and PDE were as previously reported [16, 20] . Samples were run on an ABI-Prism 7000 Sequence Detection system (Applied Biosystems, Foster City, CA) and results were analyzed by matched software and expressed as relative quantification. Relative gene expression was determined by normalizing to human β-actin [16, 20] . were run for 20 minutes at 80V and then at 110V for additional 80 minutes. Proteins were transferred onto PVDF membranes (Immobilon-P, Millipore, Billerica, MA) by semi-dry electroblotting and subsequently incubated in blocking buffer containing 2.5% skimmed milk. Following 60 minutes, mouse anti-ADA antibody (Abcam, Cambridge, MA) was applied at 1µg/ml. Following overnight incubation membranes were incubated for 60 minutes with HRP-labeled goat anti-mouse (Thermo-Scientific) at 1/50,000. Bands were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo-Scientific) according to the manufacturer's instructions. For immunoblot normalization, the same membranes were stripped (using a buffer containing 15g glycine, 1g SDS and 10ml Tween20), incubated in blocking buffer containing 5% BSA for 60 minutes and reprobed with mouse anti-human β-actin (Abcam) at 1/10,000 and subsequently with a HRP-labeled goat anti-mouse polyclonal antibody at 1/20,000. ADA and β-actin band density was determined using Image J densitometry software.
Immunoblot analysis
Analysis of ectonucleotidase activity
Thin layer chromatography (TLC) was performed as previously described [16, 21] . 3×10 5 Th17 cells were incubated with 2 mCi/ml [C 14 ] ADP (GE Healthcare Life Sciences) in 10mM Ca 2+ and 5mM Mg 2+ . 5µl aliquots, collected at 5, 10, 20, 40 and 60 minutes, were then analyzed for the presence of [C 14 ] ADP hydrolysis products by TLC and applied onto silica gel matrix plates (Sigma-Aldrich). [C 14 ] ADP and the radiolabeled derivatives were separated using an appropriate solvent mixture as previously described [16, 21] . Image J densitometry software was used to quantify TLC band intensity.
Statistical analysis
The normality of variable distribution was assessed by the Kolmogorov-Smirnov goodness-of-fit-test; once the hypothesis of normality was accepted (P>0.05), comparisons were performed by paired or unpaired Student t test as appropriate. A oneway analysis of variance, followed by Tukey's multiple comparisons test, was used to compare means of multiple samples. P values <0.05 were considered significant. Data were analyzed using GraphPad Prism 5 software (GraphPad software Inc; San Diego, CA) and SPSS software (IBM; Hampshire, UK).
RESULTS
Expression of CD39 marks activated Th17 cells that display heightened FOXP3 levels and contain high proportions of lymphocytes producing regulatory cytokines
The phenotype of Th17 CD39+ cells was initially assessed in PBMCs from HS. The gating strategy adopted for their identification is depicted in Fig. 1A . When compared to the Th17 CD39counterparts, Th17 CD39+ cells contained higher proportions of cells positive for the activation markers CD69, CD44 and CD25, and higher frequencies of cells positive for CD73 (the ectoenzyme working in tandem with CD39 and responsible for hydrolyzing adenosine monophosphate [AMP] into immunosuppressive adenosine). A substantive proportion of these Th17 CD39+ cells also were noted to express CD161 (a Th17 cell marker involved in the development of these cells) [22] and FOXP3 ( Fig. 1B and Supplementary Fig. 1A) .
Th17 CD39and Th17 CD39+ cells had similar expression of CCR6, IL-23R and RORC, standard Th17 cell markers ( Fig. 1B and Supplementary Fig. 1A) . Analysis of the cytokine profile showed that compared to their Th17 CD39counterparts, Th17 CD39+ cells contained higher proportions of IL-10 + and TGF-β + cells, lower frequencies of TNF-α producing lymphocytes and tended to have lower proportions of IFNγ + cells ( Fig. 1C and   Supplementary Fig. 1B) .
Therefore, expression of CD39 defines Th17 cells with an activated phenotype that contain increased proportions of lymphocytes positive for FOXP3 and immunomodulatory cytokines.
Th17 CD39+ cells from AILD patients are decreased, less activated and contain lower proportions of FOXP3 + and IL-10 producing lymphocytes than in health
The proportion of circulating Th17 CD39+ cells was decreased amongst PBMCs from AILD patients compared to DC and HS ( Fig. 2A) , with ASC patients displaying the lowest frequency (Fig. 2B) . Frequencies of Th17 CD39+ cells were lower in AILD patients with concomitant IBD than in those without IBD (Fig. 2C) Th17 CD39+ cell frequencies were not significantly different in AILD patients at remission or during relapse ( Fig. 2D) and between patients treated with prednisolone alone or with prednisolone in association with azathioprine or MMF (Fig. 2D) .
In order to evaluate whether in AILD the decreased frequency of blood Th17 CD39+ cells resulted from aberrant homing of these cells to the liver, we investigated the presence of CD4 + and CD39 + cells in 7 liver biopsy samples. In all biopsies, whether taken during active or controlled disease, there were likewise low numbers of CD4 + CD39 + cells ( Supplementary Fig. 2A,B) .
Given that DC and HS displayed comparable frequencies of circulating Th17 CD39+ cells, only cells from HS were used as control for the subsequent experiments. Compared to HS, Th17 CD39+ cells from AILD patients had lower frequencies of CD44 + , CD25 + , CD161 + and FOXP3 + cells (Fig. 3A) , higher proportions of TNF-α + and lower frequencies of IL-10 + lymphocytes (Fig. 3B) . The proportion of TGF-β producing Th17 CD39+ cells was negatively correlated with AST, γGT and IgG levels (Fig. 3C). 
In AILD Th17 CD39+ cells show impaired ectoenzymatic activity
We next determined whether Th17 CD39+ cells exhibited ectoenzymatic activity. We initially assessed the proportion of cells positive for CD73 -the ectoenzyme converting AMP into adenosine -within the Th17 CD39+ subset. As shown in Fig. 4A , there is a lower proportion of Th17 CD39+ cells expressing CD73 in AILD patients compared to HS.
The ectoenzymatic activity of Th17 CD39+ cells was then assessed by TLC. As depicted in Fig. 4B,C , Th17 CD39+ cells from AILD patients displayed defective ADP hydrolysis, generating lower AMP and adenosine levels, at short and long reaction times.
Reduced Th17 CD39+ cell suppressive properties in AILD patients
Compared to Th17 CD39-, Th17 CD39+ cells were more effective at suppressing CD4 + CD25responder cell proliferation, IFNγ and IL-17 production (determined as proportion of IFNγ and IL-17 producing lymphocytes) ( Fig. 5A, B) . Inhibition of responder cell proliferation and IL-17 production following addition of Th17 CD39+ cells was markedly lower in AILD than HS (Fig. 5B) . In both HS and AILD no control of responder cell proliferation and effector cytokine production was observed following addition of Th17 CD39cells.
Th17 CD39+ cells from AILD patients show decreased A2A adenosine receptor expression
We then explored the mechanisms possibly accounting for low CD39 expression in Th17 cells from AILD patients. As this could result from low adenosinergic responsiveness due to altered adenosine receptor expression, we tested the expression of A1, A2A, A2B and A3 adenosine receptors at mRNA level. Th17 cells from AILD patients displayed markedly lower levels of A2A adenosine receptor compared to HS (Fig. 6A) . We also explored whether low levels of CD39 expression were linked directly with high levels of PDE -the enzymes degrading the phosphodiester cAMP bond -or high levels of adenosine catalysis, because of heightened ADA expression.
However, no substantive differences in the expression of PDE4A, PDE4B and ADA were noted between Th17 cells from AILD patients or from HS (Fig. 6B,C) . As ADA is functional at the cell surface, when directly interacting with CD26, the expression of which is increased on human Th17 cells [23] , the frequency of CD26 + cells was sought.
As shown in Fig. 6D , no significant differences were again observed in the proportion of CD26 + cells within the Th17 CD39+ subset between AILD and HS.
DISCUSSION
The present study shows that expression of the CD39 ectonucleotidase, which confers immunoregulatory properties upon Th17 cells, is diminished in patients with juvenile AILD. This decrease is associated with impaired generation of immunosuppressive adenosine and defective regulatory properties. The resulting persistence of Th17 cells in such an inflammatory state might play a role in perpetuation of liver injury, either inflicting or being permissive of tissue damage. Our data also indicate that deficient A2A adenosine receptor expression is responsible for impaired CD39 expression by Th17 cells in AILD.
The phenotypic analysis of Th17 CD39+ cells in our patients reveals a complex profile.
While maintaining conventional Th17 cell markers, such as CCR6, IL-23R and RORC, and overexpressing activation markers and CD161 -a molecule involved in Th17 cell generation [22] -they also overexpress regulatory molecules, such as FOXP3 and IL-10.
That Th17 cells can undergo regulation and acquire immunosuppressive properties has been elegantly documented by Esplugues et al in a mouse model of colitis, where pathogenic Th17 cells could be redirected and controlled in the small intestine, becoming capable of producing the immunoregulatory cytokine IL-10 [24] . Recently, a study from the same group has shown that effector Th17 cells can 'transdifferentiate' into regulatory cells with potent suppressive capacity in in vivo anti-CD3 and bacterial induced models of inflammation [25] . These authors propose that acquisition of immunoregulatory properties by Th17 cells might provide a mechanism to limit their pathogenic potential [24] . Whether Th17 cells that acquire immunosuppressive phenotypes and function also co-express the CD39 ectonucleotidase was, however, untested.
A comparable clinical study from our group has shown that acquisition of regulatory properties by effector Th17 cells is characterized by up-regulation of CD39, with Th17 CD39+ cells exhibiting immunosuppressive properties comparable to those exerted by T-regs, despite retaining some effector Th17 cell phenotypic features [16] .
We report herein that patients with juvenile AILD have decreased proportions of circulating Th17 CD39+ cells, the lowest frequencies being present in patients with ASC.
Interestingly, echoing what was reported in Crohn disease [16] , we observed particularly low frequencies of these cells in AILD patients with associated IBD. The reasons as to why the intestinal inflammatory milieu might influence number and function of Th17 CD39+ cells remains to be investigated.
Whether lower proportions of Th17 CD39+ cells are the result of the immunosuppressive treatment rather than being an intrinsic defect of Th17 cells in acquiring immunoregulatory properties cannot be conclusively answered by our findings. However, we observed no significant differences in the proportion of Th17 CD39+ cells between patients tested at remission or during relapse, when higher doses of immunosuppressive drugs were used.
Moreover, patients on prednisolone monotherapy had proportions of Th17 CD39+ cells similar to those on prednisolone and azathioprine or MMF, suggesting that these drug regimens do not impact differentially on CD39 expression by Th17 cells.
The decreased Th17 CD39+ cell frequency observed in the circulation is unlikely to result from homing of these cells to the liver, as indicated by the immunohistochemistry and immunofluorescence data ( Supplementary Fig. 2A,B) .
When compared to HS, Th17 CD39+ cells of patients with AILD exhibit a less activated phenotype, but more pro-inflammatory properties, as indicated by lower proportions of FOXP3 + and IL-10 + cells and higher frequencies of TNF-α producing lymphocytes.
These findings suggest that these cells retain their effector potential, as confirmed by a decreased ability to generate adenosine, likely to result from concurrent impaired expression of the CD73 ectoenzyme.
Interestingly, Th17 CD39+ cells do retain the ability to control liver damaging immune reactions, as indicated by the strong negative correlation between the proportion of TGFβ producing Th17 CD39+ cells and biochemical indices of disease activity. This immunoregulatory potential, however, may be hindered by their deficient number.
The co-culture experiments performed in the present paper indicate that CD39 is pivotal in conferring immunomodulatory functions to Th17 cells in health, where the effector function (proliferation and cytokine production) of responder cells is effectively dampened upon addition of these cells. Conversely, these immunomodulatory properties are impaired in AILD suggesting that Th17 CD39+ cells can persist at an inflammatory state and be instrumental to liver damage. Decreased CD39 expression on Th17 cells is likely to derive, at least in part, from low levels of the A2A adenosine receptor, with consequent decline in the anti-inflammatory activity of adenosine.
Altered immunoregulation could also derive from low generation of adenosine by the Th17 cells themselves or by CD39 + T-regs, as previously shown in AIH [17] , or by resistance of Th17 cells to adenosine [16] . The comparable levels of ADA, PDE4A and PDE4B expression between patients and healthy individuals exclude the possibility that the inability to up-regulate CD39 by effector Th17 cells is linked to increased adenosine catalysis or to augmented degradation of cAMP.
Another possibility for impaired up-regulation of CD39 by Th17 cells -not tested in the current manuscript -would involve defective cAMP signaling, which induces CD39 mRNA transcription upon activation of pathways involving the cAMP dependent protein kinase (PKA). These pathways also involve the phosphoinositide 3-kinase (PI3K) and extracellular signal-regulated kinases (ERK), and culminate with the phosphorylation of the cAMP-response element-binding protein (CREB) [26] .
In conclusion, it is likely that Th17 cells are involved in the pathogenesis of autoimmune 
